⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 30, 2024International Journal of Clinical Pharmacology and Therapeutics

Pharmacokinetic, bioequivalence, and safety assessments of two brands of 30-mg nifedipine controlled-release formulations in Chinese healthy subjects

Huan Lu Zhou Fei Cuijie Rui H.Y. You Wenhao Zhang Yaxin Zhang Juefang Ding Shunbo Zhao Qiang Wu

View Full Paper

Ask AI

Bookmark

Share

Abstract

This study aimed to analyze the pharmacokinetic (PK) characteristics, safety, and bioequivalence (BE) of a test (T) preparation of a nifedipine controlled-release tablet and the reference (R) drug (Adalat GTIS) in Chinese study participants in the context of fasting and postprandial states.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lu et al. (2024) studied this question.

synapsesocial.com/papers/68e5e80fb6db64358757d125 https://doi.org/10.5414/cp204605

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comparative Bioequivalence and Food Effect of Two Formulations of 30‐mg Nifedipine Controlled‐Release Tablets in Healthy Chinese Adults2024 · 3 citations
2Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administrationOriginal Research · 2010 · 20 citations
3Nifedipine 20 mg Brands' Bioequivalency and Bioavailability in Healthy Human Subjects2024
4Formulation of long‐acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patientsRCT · 2007 · 15 citations
5Assessment of Pharmacokinetics and Safety with Bioequivalence of the Nitroglycerin Sublingual Tablets of Two Formulations in Chinese Healthy Subjects: A Bioequivalence Study2025